Psychedelics field looks ahead after FDA advisers' rejection.
Science June 14, 2024 DOI: 10.1126/science.adr0286 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary or analysis Peer reviewed |
|---|---|
| Keywords | Psychedelic-medicine MDMA-Therapy Clinical-trials Drug-regulation Mental-health-treatment |
| Citations | 3 |
| Key points | Argues that researchers are analyzing the FDA's rejection of MDMA-assisted PTSD therapy to identify methodological shortcomings and improve future psychedelic studies. |
Abstract
Reeling from negative vote on MDMA-assisted PTSD therapy, researchers seek lessons for future studies.
Citations in the library
Cited by 3
- What should constitute a control condition in psychedelic drug trials? Nature Mental Health October 1, 2024
- Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning‐Based Advanced Perspectives Advanced Science March 20, 2025
- Circuit-informed modulation of traumatic memory in PTSD: integrating extinction, suppression, and reconsolidation. Molecular Psychiatry June 1, 2026